Tesamorelin 10mg· 10mg

Tesamorelin binds the GHRH receptor with affinity comparable to native GHRH, activating Gas, elevating intracellular cAMP, and stimulating pulsatile growth hormone release from pituitary somatotrophs. The N-terminal trans-3-hexenoyl modification blocks recognition by dipeptidyl peptidase-4, the principal degradative enzyme of native GHRH, extending plasma half-life from minutes to approximately 26 to 38 minutes.

Downstream consequences of repeated GHRH receptor activation include sustained elevations of IGF-1, which mediates many of the metabolic effects observed in clinical research. Tesamorelin administration in research populations has been associated with reductions in visceral adipose tissue, decreased hepatic triglyceride content, and modest changes in lipid profiles. Mechanistic explanations include increased lipolysis in visceral adipose depots, altered hepatic substrate handling, and improved insulin sensitivity in specific tissue compartments.